Pacira BioSciences Appoints New CEO, Dr. David Stack

TL;DR

Pacira brings back former CEO David Stack, Nelson steps down.

AI Summary

Pacira BioSciences, Inc. announced on June 11, 2024, the appointment of Dr. David M. Stack as Chief Executive Officer and a member of the Board of Directors, effective immediately. Dr. Stack, who previously served as CEO of Pacira from 2007 to 2011, will also receive an annual base salary of $600,000 and equity awards. The company also announced the departure of its former CEO, Lewis G. Nelson, M.D., who will transition to an advisory role.

Why It Matters

The appointment of a new CEO, especially one with prior experience at the company, can signal a strategic shift or a renewed focus on growth and operational efficiency.

Risk Assessment

Risk Level: medium — Leadership changes, especially at the CEO level, can introduce uncertainty regarding future strategy and execution.

Key Numbers

• $600,000 — CEO Salary (Annual base salary for new CEO Dr. David Stack.)

Key Players & Entities

• Pacira BioSciences, Inc. (company) — Registrant
• David M. Stack (person) — Newly appointed CEO and Board Member
• Lewis G. Nelson, M.D. (person) — Former CEO transitioning to advisory role
• $600,000 (dollar_amount) — Dr. Stack's annual base salary

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share PCRX Nasdaq Global Select Mar
• $3,200 — ding June 30, 2025 for consideration of $3,200 per calendar quarter for up to eight ho

Filing Documents

• pcrx-20240611.htm (8-K) — 35KB
• 0001396814-24-000057.txt ( ) — 157KB
• pcrx-20240611.xsd (EX-101.SCH) — 2KB
• pcrx-20240611_lab.xml (EX-101.LAB) — 21KB
• pcrx-20240611_pre.xml (EX-101.PRE) — 12KB
• pcrx-20240611_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 11, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") in San Diego, California. As of April 15, 2024, the record date for the Annual Meeting, 46,523,185 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted on, and approved, at the Annual Meeting is as follows: Proposal 1 — Election of four Class I directors to hold office until the 2027 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified. Nominee: For Withhold Broker Non-Votes Laura Brege 20,659,043 20,779,899 2,676,760 Mark Froimson 40,275,000 1,163,942 2,676,760 Mark Kronenfeld 31,252,640 10,186,302 2,676,760 Michael Yang 40,666,349 772,593 2,676,760 Proposal 2 — Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. For Against Abstain 43,901,001 204,074 10,627 Proposal 3 — Advisory vote to approve the compensation of the Company's named executive officers. For Against Abstain Broker Non-Votes 37,228,983 4,087,635 122,324 2,676,760 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PACIRA BIOSCIENCES, INC. (REGISTRANT) Dated: June 13, 2024 By: /s/ KRISTEN WILLIAMS Kristen Williams Chief Administrative Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR